Epioxa improved corneal curvature and demonstrated visual acuity gains and safety in pediatric patients with keratoconus, according to a presenter at the American Association for Pediatric Ophthalmology and Strabismus meeting.
Michael B. Raizman, MD, of Ophthalmic Consultants of Boston, presented the results of a subgroup analysis of a phase 3 multicenter trial in which 30 eyes of 22 pediatric patients between the age of 13 to 17 years old were assigned to 2:1 treatment with Epioxa (riboflavin 5’-phosphate ophthalmic solution 0.239% and 0.177%, Glaukos), the first epithelium-on cross-linking